Skip to main content
Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
40.64
-2.46 (-5.71%)
Mar 13, 2025, 4:00 PM EST - Market closed

Guardant Health Revenue by Segment
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Precision Oncology Testing
687.94M 645.54M 598.36M 557.09M 514.25M 485.86M 454.49M 421.31M
Precision Oncology Testing Growth
33.77% 32.87% 31.66% 32.23% 31.17% 32.40% 32.05% 29.74%
Development Services
51.08M 46.72M 45.45M 46.64M 49.70M 49.93M 55.67M 60.85M
Development Services Growth
2.78% -6.43% -18.36% -23.35% -13.55% -21.74% -12.95% -8.32%

Revenue by Geography
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Unitied States
697.16M 648.18M 603.81M 564.96M 526.52M 501.72M 477.08M 448.66M
Unitied States Growth
32.41% 29.19% 26.56% 25.92% 25.18% 23.95% 24.21% 20.89%
International
42.12M 44.07M 40.00M 38.76M 37.42M 34.06M 33.08M 33.50M
International Growth
12.56% 29.39% 20.93% 15.73% 29.41% 31.11% 37.64% 67.85%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.